ACVR1 Inhibitors for Neurorepair in Demyelinating Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as multiple sclerosis, Alzheimer's, and Parkinson's do not effectively address the cellular or molecular basis of neuronal degeneration and lack direct effects on central nervous system repair, leading to irreversible tissue injury and increased disabilities.
Innovation Solution
Administration of inhibitors of the bone morphogenetic protein (BMP) receptor, specifically ACVR1 (Alk2), or agents that modulate the ligand for ACVR1 (activin) to promote neurorepair, remyelination, and prevent demyelination, using compounds like LDN-212854, dorsomorphin, and other small molecule inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunomodulatory therapies are used for CNS demyelinating diseases, then disease symptoms are ameliorated, but direct effects on CNS repair and remyelination are lacking
Solution Approach 1:
The patent uses small molecule inhibitors (such as LDN-193189, dorsomorphin, DMH1) as intermediary agents that specifically target BMP receptor signaling pathways. These intermediaries block the inhibitory signals that prevent remyelination, thereby enabling CNS repair without interfering with immunomodulatory therapies. The inhibitors act as molecular mediators between the pathological environment and the reparative processes of oligodendrocyte precursor cells.
Solution Approach 2:
The patent changes the biochemical parameter of BMP receptor signaling activity by introducing specific inhibitors. This parameter change (reducing BMP pathway activation) removes the extrinsic inhibition on remyelination, allowing oligodendrocyte precursor cells to differentiate and remyelinate axons effectively, thereby adding CNS repair capability to the therapeutic regimen.
2Duration of action of stationary object
If neurodegenerative diseases progress without targeted therapy, then disease duration increases, but irreversible tissue injury and neuronal death occur
Solution Approach 1:
The patent applies preliminary action by administering BMP receptor inhibitors early in the disease course, before irreversible neuronal death occurs. The inhibitors proactively block the inhibitory signaling environment, preparing the tissue for remyelination and neurorepair. This preliminary intervention prevents the progression to irreversible damage by establishing a permissive environment for repair mechanisms.
Solution Approach 2:
The patent employs preliminary anti-action by using inhibitors to counteract the harmful BMP signaling pathway before it can fully suppress remyelination. The inhibitors apply an opposing force to the pathological signaling, neutralizing the extrinsic inhibition on oligodendrocyte differentiation and protecting neuronal tissue integrity throughout the disease course.
3Object-affected harmful factors
If extrinsic inhibition of remyelination is present in chronic neuroinflammatory models, then remyelination capacity is suppressed, but therapeutic intervention can overcome this inhibition
Solution Approach 1:
The patent converts the harmful extrinsic inhibition (BMP signaling) into a benefit by using specific inhibitors to block this pathway. The inhibitors transform the pathological environment from one that suppresses remyelination to one that promotes it. By blocking the harmful signaling, the patent enables oligodendrocyte precursor cells to differentiate and remyelinate, thereby converting the inhibitory environment into a reparative one.
Data Source
AI summary
Compositions and methods to treat or prevent neurodegeneration in a mammal comprising administering to the mammal in need thereof an effective amount of an inhibitor of ACVR1 (Alk2).